Fitness product manufacturer to launch new equipment as part of Philips agreement
Fitness and wellness product manufacturer Dyaco is set to launch a new line of medical and rehabilitation equipment as part of a global brand licensing agreement with Philips.
The partnership comes where there is an increasing active ageing population and a growing need for physical therapy interventions and programming in medical and rehabilitation environments.
On the new partnership, Daniel Clayton, president of Dyaco Commercial and Medical Division, said: “We’re delighted to launch this innovative line of Philips medical fitness equipment to the healthcare marketplace. The strategic brand license partnership with Philips is a very significant enhancement to the Dyaco portfolio of brands. We have a unique offering of highly specified medical equipment designed to improve people’s lives. As we extend Dyaco’s reach into the medical and rehabilitation markets, the impact and credibility of the Philips brand make this the ideal partnership to deliver these much-needed, innovative solutions.”
The equipment has been developed using rehabilitation strategies and technologies aim to address the active ageing population and a multitude of patient deficiencies to enhance recovery outcomes. The initial launch product line includes a medical and rehab treadmill, recumbent bike, upright bike, recumbent stepper and stepper with removable seat for wheelchair access.
With tailored adjustments and proprietary features, the products could enable clinicians and therapists the ability to prescribe physical therapy programs for an individual’s specific needs.
Spencer Ramsey, senior director Global Branding Licensing at Philips said: “We are very excited about our new partnership with Dyaco International and developing this important category in Philips’ healthcare brand licensing portfolio in both the professional and home sectors, helping to improve people’s lives and deliver better outcomes.”
The Philips line of medical and rehabilitation equipment is due to launch in the US market the first quarter of 2019, with further market rollouts later in year.